TrialCancer immunology research2015

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Rachel Lubong Sabado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.